[1] Bae JW, Woo SI, Lee J, et al.mHealth Interventions for Lifestyle and Risk Factor Modification in Coronary Heart Disease: Randomized Controlled Trial[J]. JMIR Mhealth Uhealth, 2021,9(9):2992-2998.
[2] Tao S, Tang X, Yu L, et al.Prognosis of coronary heart disease after percutaneous coronary intervention: a bibliometric analysis over the period 2004-2022[J]. Eur J Med Res, 2023,28(1):311-314.
[3] 张小敏,肖栋,柏中胜,等. 定量血流分数测量对经皮冠状动脉介入治疗后患者主要不良心血管事件发生的预测价值[J]. 中国介入心脏病学杂志,2023,31(7):532-540.
[4] 袁勇程,刘尚军. 氯吡格雷和替格瑞洛对老年冠心病患者PCI术后血小板功能、炎性反应及主要不良心血管事件的影响[J]. 中国药物应用与监测,2022,19(2):72-75.
[5] Ikezaki H, Lim E, Cupples LA,et al.Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study[J]. J Am Heart Assoc, 2021 ,10(5):1914-1918.
[6] 孙俊翔,陈燕春,殷云杰,等. 脂蛋白(a)与老年冠心病病人PCI术后心肌损伤关系的研究[J]. 实用老年医学,2022,36(8):818-821.
[7] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.稳定性冠心病基层诊疗指南(2020年)[J].中华全科医师杂志, 2021, 20(3):265-273.
[8] 史玛诺,冯珊珊,于源. 高龄冠心病患者PCI术后发生MACE的影响因素[J]. 心血管康复医学杂志,2022,31(6):688-692.
[9] 甘程,莫云秋,顾亚威.不同调脂药物配合替罗非班对老年冠心病PCI术后患者MACE发生率的影响探析[J].中国科技期刊数据库医药, 2023,14(5):76-79.
[10] Rikhi R, Schaich CL, Hafzalla GW, et al.Small Dense Low-Density Lipoprotein Cholesterol and Coronary Artery Calcification in the Multi-Ethnic Study of Atherosclerosis[J]. Eur J Prev Cardiol, 2024,12(3):49-52.
[11] Nomura SO, Karger AB, Garg P,et al.Small dense low-density lipoprotein cholesterol compared to other lipoprotein biomarkers for predicting coronary heart disease among individuals with normal fasting glucose: The Multi-Ethnic Study of Atherosclerosis[J]. Am J Prev Cardiol, 2022,13(4):1004-1009.
[12] 郝岩,潘洋,高洪瑞,等.术前血清脂蛋白a和低密度脂蛋白胆固醇预测急性冠状动脉综合征患者PCI术后短期不良预后价值的比较[J].临床心血管病杂志, 2020, 36(12):1115-1119.
[13] 陆哲远,黄颖. 血脂蛋白a联合MHR对NSTE-ACS患者冠状动脉病变严重程度及预后的评估价值[J]. 中国临床研究,2022,35(1):16-20. |
